依托泊苷联合顺铂化疗方案对常规治疗失败的去势抵抗性前列腺癌患者肿瘤标志物水平及生存情况的影响

Effects of etoposide combined with cisplatin chemotherapy on tumor markers levels and survival in patients with castration-resistant prostate cancer who failed conventional treatment

目的探讨依托泊苷联合顺铂化疗方案对常规治疗失败的去势抵抗性前列腺癌患者肿瘤标志物水平及生存情况的影响。方法选取2019年6月至2021年6月陕西中医药大学附属医院和陕西中医药大学第二附属医院共同收治的80例常规治疗失败的去势抵抗性前列腺癌患者为研究对象,随机将其分为对照组和观察组,各40例。对照组采用多西他赛联合泼尼松化疗方案治疗,观察组采用依托泊苷联合顺铂化疗方案治疗。比较两组的治疗效果。结果观察组的治疗总有效率高于对照组(P<0.05)。治疗后,观察组的前列腺特异性抗原(PSA)、癌胚抗原(CEA)、前列腺特异性酸性磷酸酶(PSAP)水平低于对照组(P<0.05)。观察组的无进展生存期(PFS)、总生存期(OS)长于对照组(P<0.05);治疗后,观察组的前列腺癌患者生活质量测定量表(FACT-P)评分高于对照组(P<0.05)。结论依托泊苷联合顺铂化疗方案治疗常规治疗失败的去势抵抗性前列腺癌患者可提高临床疗效,降低肿瘤标志物水平,改善患者的生存情况,值得推广。

Objective To investigate the effects of etoposide combined with cisplatin chemotherapy on tumor markers levels and survival in patients with castration-resistant prostate cancer who failed conventional treatment.Methods From June 2019 to June 2021,80 patients with castration-resistant prostate cancer who failed in conventional treatment admitted in Affiliated Hospital of Shaanxi University of Chinese Medicine and the Second Affiliated Hospital of Shaanxi University of Chinese Medicine were selected as the research objects.The patients were randomly divided into control group and observation group,with 40 cases in each group.The control group was treated with docetaxel combined with prednisone chemotherapy,and the observation group was treated with etoposide combined with cisplatin chemotherapy.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).After treatment,the levels of prostate specific antigen(PSA),carcinoembryonic antigen(CEA)and prostate specific acid phosphatase(PSAP)in the observation group were lower than those in the control group(P<0.05).The progression-free survival(PFS)and overall survival(OS)of the observation group were longer than those of the control group(P<0.05);after treatment,the Functional Assessment of Cancer Therapy-Prostate(FACT-P)score in the observation group was higher than that in the control group(P<0.05).Conclusion Etoposide combined with cisplatin chemotherapy in the treatment of castration-resistant prostate cancer patients with conventional treatment failure can improve the clinical efficacy,reduce the levels of tumor markers and improve the survival of patients,which is worthy of promotion.